Longeveron Inc. (LGVN) stock
LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.66−0.16 (-8.79%)
Close on Nov 20, 2026Market cap $52.92MP/E –Yield –
Longeveron operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Longeveron's operating income for the twelve months ending Jun 30, 2026 was -$23.66M. For fiscal 2025 it was -$23.29M. The highest annual figure on record is -$3.78M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.29M | – |
| FY2024 | Dec 31, 2024 | -$16.52M | – |
| FY2023 | Dec 31, 2023 | -$21.03M | – |
| FY2022 | Dec 31, 2022 | -$18.04M | – |
| FY2021 | Dec 31, 2021 | -$17.46M | – |
| FY2020 | Dec 31, 2020 | -$3.78M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.17M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.78M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.31M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.44M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.72M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.22M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.39M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.03M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.91M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.06M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.46M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$958.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.23M | – |
| Q1 FY2020 | Mar 31, 2020 | -$213.00K | – |
See a number that looks wrong?